Dilated cardiomypathy : ventricular systolic dysfunction

What is the dilated cardiomyopathy (DCMP)

Dilated cardiomyopathy (DCMP) is the most common subtype of nonischemic cardiomyopathy and comprises over 90% of cases.

Dilated cardiomyopathy refers to the final common pathway of a group of diseases rather than a single diagnosis.

In general, there is myocardial dysfunction from progressive dilation and diminishing contractility (systolic dysfunction, FEVG <40%). (Relatively normal diastolic function)

These changes, by definition, are not a result of underlying extramyocardial pathological conditions such as hypertension, coronary artery disease, valvular disease, or congenital abnormalities.

If these conditions are present, given their high prevalence, DCMP should only be diagnosed if the degree of contractile dysfunction is out of proportion to the underlying disease burden.

Histological hallmark of DCMP

Progressive interstitial fibrosis with a numerical decrease of myocyte

Reduced stroke volume ➜ Decreased cardiac output ➜ Congestive heart failure

Main purpose of MRI
– Differentiation from an ischemic origin (DE-MRI)
– Prediction of functional improvement (DE-MRI)

Cine MRI
– LV chamber diameter > 6.0cm (at mid-ventricular level)

Cine MRI (short axis), global LV dilatation (>6cm)

DE-MRI
– Patchy enhancement of longitudinal striae of midwall (28%) or epicardial wall
Worse prognosis than non-enhancement lesions
– Subendocardial, transmural (13%)
– No enhancement (59%)

linear DE at mid-layer of basal septal and basal inferior LV myocardium
Cine MRI (short axis)
diffuse thinning of the myocardial wall and dilated left ventricular cavity with associated LV global severe hypokinesia/akinesia

DDx.
– Ischemic heart disease
➜ delayed enhancement at vascular territory
➜ Ischemic heart disease must involve subendocardial wall (subendocardial or transmural)

Ischemic CMPDilated CMP
ECGQ or ST abnormalityST or T abnormality
PathologyNecrosis, fibrosis, hibernationFibrosis, myocyte size variation
DiagnosisCoronary angiography, Viability studyCoronary angiography, Biopsy
DE-MRISubendocardial or transmural enhancementNo enhancement Mid wall or patchy enhancement

Reference)
Charles S. White, Linda B. Haramati, Joseph Jen-Sho Chen, and Jeffrey M. Levsky (2014), Cardiac Imaging, Oxford university press

0 0 votes
Article Rating
Subscribe
Notify of
guest
0 Comments
Inline Feedbacks
View all comments
0
Would love your thoughts, please comment.x
()
x